

# Qiagen, Servier to develop CDx for acute myeloid leukemia drug

April 2023—Qiagen has entered into a strategic partnership with Servier to develop a companion diagnostic test for Tibsovo (ivosidenib), an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of acute myeloid leukemia. Under the agreement, Qiagen will develop and validate a real-time in vitro PCR test that can be used to detect *IDH1* gene mutations in patients with AML in whole blood and bone marrow aspirates. The companion diagnostic will run on Qiagen's Rotor-Gene Q MDx instrument.

[Qiagen](#), 240-686-7700